 |
|
|
| Internet Search |
|
Stock Search |
|
|
|
|
|
PENWEST PHARM CO, (PPCO) Stock Rating Learn More
| Our Overall Rating on PENWEST PHARM CO, PPCO is Not Available | | Penwest Pharmaceuticals Co. develops pharmaceutical products based on proprietary oral drug delivery technologies primarily in North America and Europe. The company is developing two drug development pipelines, which include oxymorphone ER, an extended release formulation of oxymorphone, a narcotic analgesic being developed for twice-a-day dosing in patients with moderate to severe pain requiring opioid therapy for an extended period of time; and PW2101, a beta blocker intended for the treatment of hypertension and angina. Its drug delivery technologies include TIMERx, an extended release delivery system that is adaptable to soluble and insoluble drugs, as well as flexible for a various controlled release profiles; Geminex, a dual drug delivery system to provide independent release of different active ingredients contained in a drug; SyncroDose, a drug delivery system to release the active ingredient of a drug at the desired site and time in the digestive tract; and Gastroretentive system, a drug delivery system to provide controlled release delivery of drugs that are absorbed in the stomach and upper portions of the GI tract, without a loss of bioavailability. Penwest Pharmaceuticals is also developing various additional product candidates in areas, such as edema, epilepsy, schizophrenia, and depression. The company has a collaboration agreement with Endo Pharmaceuticals, Inc. for the development of oxymorphone ER product. Penwest Pharmaceuticals is headquartered in Danbury, Connecticut. | | Our Not Available Rating on PPCO was issued on 11/22/2008 |
PENWEST PHARM CO Technical Rating
|
|
|
|
